Considering the known contribution of FABP5 to PC progression, these findings provide additional evidence that FABP5 inhibition is a sound therapeutic strategy to reduce tumor growth and metastasis and potentially blunt the development of taxane resistance. This evidence concerns the gene FABP5 and neoplasm.